Skip to main content

Table 3 Multivariate Cox proportional hazards model for disease-free survival and cancer-specific survival

From: Metformin increases survival in hormone receptor-positive, HER2-positive breast cancer patients with diabetes

  Disease-free survival Cancer-specific survival
  P-value Hazard ratio 95 % CI P-value Hazard ratio 95 % CI
Metformin       
 Metformin   1    1  
 Non-metformin versus metformin 0.025 1.59 1.06 to 2.39 0.009 1.85 1.17 to 2.92
 Non-DM versus metformin 0.483 0.90 0.66 to 1.22 0.519 0.89 0.62 to 1.27
Age, years       
 ≤50 0.584 1.04 0.92 to 1.17 0.106 0.89 0.77 to 1.03
Body mass index, kg/m2       
 High   1    1  
 Low versus high 0.009 1.17 1.1 to 1.17 0.018 1.52 1.08 to 2.14
 Normal versus high 0.639 1.03 0.91 to 1.17 0.597 1.04 0.90 to 1.21
Tumor size, cm       
 T ≥2 <0.001 2.03 1.78 to 2.31 <0.001 2.18 1.86 to 2.56
Node metastasis       
 Node positive <0.001 2.59 2.26 to 2.96 <0.001 3.09 2.63 to 3.64
Estrogen receptor status       
 Positive 0.009 0.79 0.66 to 0.94 0.026 0.78 0.63 to 0.97
Progesterone receptor status       
 Positive 0.004 0.80 0.68 to 0.93 0.001 0.72 0.60 to 0.87
HER2 status       
 Positive <0.001 1.27 1.13 to 1.44 <0.001 1.29 1.12 to 1.49
Chemotherapy       
 Yes <0.001 0.70 0.58 to 0.84 0.098 0.82 0.65 to 1.04
Endocrine therapy       
 Yes 0.312 0.91 0.75 to 1.10 0.108 0.83 0.67 to 1.04
  1. HER2, human epidermal growth factor receptor-2; DM, diabestes mellitus